Recent Event Highlights: Sensex Index Rises to Two-Month High; Tata Motors Advances With Car Sales - Bloomberg, Nifty hits 5100 amid volatility BPCL JSPL top gainers - Moneycontrol.com, Tata Steel, Cipla, KPIT Cummins, Mundra: India Equity Preview - Bloomberg, India's Cipla says gets govt demand on drug pricing - Reuters, US' Gilead appeals against patent rejection of AIDS drug Viread - Economic Times, NPPA slaps Rs 20-cr fine on Cipla for overcharging, and 144 more...
Created by dipity on Mar 16, 2009
Last updated: 11/02/10 at 02:27 PM
Cipla has no followers yet. Be the first one to follow.
Sensex Index Rises to Two-Month High; Tata Motors Advances With Car SalesBloombergCipla Ltd. (CIPLA IN) fell 1.1 percent to 348.1 rupees. The drugmaker got notices from the Indian government's National Pharmaceutical Pricing Authority ...
Nifty hits 5100 amid volatility BPCL JSPL top gainersMoneycontrol.comHowever, selling in TCS, Infosys, Reliance Communications, Wipro, Cipla and Siemens capped the gains to some extent. The Sensex was trading at 17053, ...Nifty trades in narrow range of 5070-5120 RIL slips 2Moneycontrol.comNifty trades below 5100 amid volatility RIL SAIL dipMoneycontrol.comall 6 news articles »
Tata Steel, Cipla, KPIT Cummins, Mundra: India Equity PreviewBloombergCipla Ltd. (CIPLA IN): The drugmaker got notices from the Indian government's National Pharmaceutical Pricing Authority demanding as much as 201.51 million ...India up despite weak AsiaEquitymaster.comall 57 news articles »
India's Cipla says gets govt demand on drug pricingReutersMUMBAI, Dec 7 (Reuters) - India's Cipla Ltd (CIPL.BO) has received a demand notice from a government agency for 201.4 million rupees ($4.3 million) for ...Cipla gets notice for overpricing drugs; denies liabilitydomain-BCipla weakens as regulator slaps fine for overpricing drugsIndia Infoline.comNPPA slaps Rs 20-cr fine on CiplaEconomic TimesBusiness Standard -NASDAQ -Equity Bullsall 14 news articles »
US' Gilead appeals against patent rejection of AIDS drug VireadEconomic TimesIn August, the Indian Patent Office in Delhi shot down two patents sought by the US firm for Viread after patient groups and Indian company Cipla challenged ...and more »
...and the company has received legal advice that entire amounts demanded by the government are not tenable and sustainable," Cipla said. In July also, Cipla had received notices from NPPA for alleged over-pricing of two drugs--Salbutamol and Norfloxacin. ...
Sensex northbound; ACC, Hindalco, Grasim, Cipla top gainersMoneycontrol.comIn the largecap space, Cipla was the top gainer on the Nifty with 3% gain. Reliance Capital, ACC, Reliance Power, Hindalco and Grasim were up 2.5-2.7% each. ...and more »
...to close at Rs 328.70. Sarabjit Kour Nangra, vice-president (research) at Angel Broking, said an alliance would boost immediately Ciplas revenues. India is, however, not new to such alliances. In March, Hyderabad-based Aurobindo Pharma inked an agreement with...
...has said that it is in discussions with multinational companies, including Pfizer, for supply contracts, but has denied any proposal for a stake sale. “Cipla has always followed a model of partnership and alliances in marketing its products, particularly overseas....
Hindu Business Line
GSK expands Aspen deal; Pfizer talks with CiplaFiercePharmaOver in India, generics maker Cipla is negotiating with several global drugmakers to supply generic products. Among those in the chase: Pfizer, ...and more »
...and addressing the growing needs of South African healthcare, Cipla Medpro has gained a competitive advantage." Jerome Smith, Cipla Medpro South Africa Ltd CEO said he was extremely proud of Frost & Sullivan's acknowledgment of the company's efforts. "Our...
Buy Cipla, says Mitesh Thacker, Technical Analyst, miteshthacker.com.
Technical Analyst, Sudarshan Sukhani is of the view that it is safer to stick with Sun Pharma, Cipla, Dr. Reddys and Ranbaxy all four are promising higher returns.
Cipla has target of Rs 350-360, says Anu Jain, Vice President-IIFL Private Wealth Management at India Infoline.
Online Latest News (blog)Nifty gains momentum; Cipla, RIL leadEconomic TimesCipla (2.79%), ITC (2.15%), Siemens (1.95%), Reliance (1.91%) and SUN Pharma (1.89%) were amongst the top Nifty gainers. ...Indian stock market daily closing report (November 23, 2009)Stock Markets ReviewSensex consolidates after two-day rally; realty gainsMoneycontrol.comSensex dips as global equities softenIndia Infoline.comUb News -Economic Timesall 309 news articles »
Buy Cipla, says Technical Analyst, Sudarshan Sukhani.
Sudarshan Sukhani of Technical Trends advises investors to buy Allahabad Bank, Cipla, ITC, Rallis India and Ranbaxy Laboratories. ... "Sudarshan Sukhani" CNBC-TV18 "Allahabad Bank" Cipla ITC "Rallis India" "Ranbaxy Laboratories" Nifty Ispat "Sesa Goa" IDFC CMC Infosys "Anil Dhirubhai Ambani Group" ADAG "Reliance Capital"
Rahul Mohindar of Viratechindia is of the view that health care is looking good on the whole that is the sector I would like to be in. Cipla has target of Rs 320.
...November 12 — At a time when the second wave of swine flu pandemic is likely in the winters, leading pharmaceutical firm Cipla Ltd. introduced a new variant of anti-flu drug Oseltamivir, called Antiflu, to treat H1N1 influenza this Wednesday. “We have launched...
Pharmaceutical firm, Cipla has announced the launch of Antiflu to treat H1N1 swine flu virus. "We have launched Oseltamivir brand, called Antiflu, which is the only flu medicine from India to be prequalified by WHO," the company said.
Mumbai, Nov. 11 As countries face shortages in the supply of drugs to treat Influenza A (HINI) or swine flu, drug-maker Cipla has indicated that it is ready to step-up its generic supplies of Oseltamivir and Zanamivir to India and other countries such
Hindu Business Line
Buy Cipla, says Technical Analyst, Sudarshan Sukhani.
Dr YK Hamied, CMD, Cipla, expects export growth mainly from anti-AIDS drugs. "We are targeting exports of over Rs 3000 crore for FY10 and have already reached Rs 1440 crore in the first six months." PART1
this video contain.danceparty conducted by us..
Cipla Discovery batch of 24th July, 2009 (Lonavala) ... Cipla Discovery
Blessed returns, no matter the nameTimes of IndiaThis was mainly due to some major units, such as Cipla, moving to states such as Himachal Pradesh and Sikkim where they were offered tax holidays. ...and more »
Cipla Q1 net profit seen up at Rs 224.3 cr: ReligareMoneycontrol.comAccording to the research firm, Cipla's June quarter sales are expected to go up by 13.4% to Rs 1368.3 crore on YoY basis. The company's net profit is ...and more »
NPPA issues notices to 471 companies for overchargingIndopiaAccording to the information available on NPPA&aposs website the 471 companies to whom the notices have been issued include Ranbaxy, Cipla, Dr Reddy&aposs, ...and more »
Buy Ranbaxy Lab on correction: MohoniMoneycontrol.comCipla is little closer to that sort of categorisation Ranbaxy is not." Disclosure: It is safe to assume that analyst and his clients may have investment in ...and more »
Zee NewsIndia seeks exemption for CFC based asthma inhalers for 2010Zee NewsNew Delhi, July 02: In a bid to give much-needed breather to lakhs of asthma patients as well pharma majors like Cipla, India has sought exemption for ...and more »
Mkts close higher; banks, power, realty, telecom gainMoneycontrol.comHowever, selling in ONGC, Power Grid, Cipla, Nalco, Hindalco, Grasim and Maruti added some volatility. The 50-share NSE Nifty remained ranged at 4300-4350 ...Mkts positive amid volatility; banks, telecom, realty upMoneycontrol.comMkts choppy in early trade; ICICI Bk, TCS, Hindalco slipMoneycontrol.comMkts extremely volatile; metals, power, realty declineMoneycontrol.comMoneycontrol.comall 6 news articles »
Aurobindo Pharma sues SA govt over AIDS drug bidsIndian ExpressSix Indian companies — including Aurobindo, Cipla and Ranbaxy — had participated in the tender but none could win the contract for around six products to ...and more »
'14 years of data exclusivity is crazy'Economic TimesCipla then took the information it had submitted to the WHO and gave it to the US FDA which was helpful. Yet, it took Cipla three years to get approval. ...and more »
Cipla has target of Rs 276: H ThukralMoneycontrol.comHemant Thukral, VP, Head Derivatives, Asian Market Securtities is of the view that Cipla has target of Rs 276. Thukral told CNBC-TV18, "As we look at the ...Suzlon Energy has target of Rs 115: H ThukralMoneycontrol.comall 17 news articles »
Nifty struggles below 4500; Cipla, M&M, Tata Steel downEconomic TimesCipla (-3.07%), M&M (-3.06%), Tata Steel (-2.88%), Wipro (-2.65%), Cairn (-2.64%) were amongst the major Nifty losers. Reliance Infrastructure (3.81%) ...Markets plummet at close; Realty, Metal indices dip over 5.5 per centdomain-BNifty breaks 4300; cement, metals, power down, IT upMoneycontrol.comall 339 news articles »
...India's position to Adcock," continued CMSA's statement. "(CMSA) reiterates that the relationship between the company and Cipla India is crucial to the future commercial success of the company, providing a continued pipeline of dossiers, and establishing...
Cipla,India's No 1 pharmaceutical company. members of cipla family work as a family member nt as an employee.
...can prevent takeovers like the proposed Adcock offer," said Wadley. Coronation Fund Manager's Quinton Ivan said almost all Cipla supplies come from Cipla India. "If at any time Cipla India can decide to terminate the supply agreement upon a change of management...
Empowering Financial Decisions
...of its principal supplier, Cipla India, to discourage Adcock from proceeding. “Given the lack of response from the CMSA (Cipla Medpro) Board, the uncertainty over the precise nature of the contractual relationship between Cipla India and CMSA, and the potential...
Cipla is growing beyond generics and is seeing opportunities well beyond. In a rare interview to NDTV Profit, Dr Yusuf Hamied, chairman, Cipla, revealed a broadening focus and the possibility of venturing into new areas.
AfricaNewsSA: ¤177m take-over bid hits snagAfricaNews, NetherlandsA R2,125-billion (about ¤177 million) bid by Adcock Ingram to take over rival generics manufacturer Cipla Medpro South Africa hangs in the balance after Cipla India said it would cancel a 20-year supply if the deal went ahead. Cipla India, which has no ...
Moneycontrol.comCipla Q4 operating margins to improve on weak rupeeMoneycontrol.com, IndiaCipla is set to announce its Q4FY09 numbers. According to CNBC-TV18 estimates, its net profit is expected to go up by 25% at Rs 225 crore versus Rs 179.5 crore. Here is a transcript of Research Analyst, Archi Damania's comments on CNBC-TV18. ...
TopNewsIndian Stock markets close negative for third session after strong ...TopNews, IndiaPharma stocks like Glenmark, Sun Pharma, Cipla, Ranbaxy Labs and Biocon declined 2-4% In the Sensex pack Maruti Suzuki, DLF and Sterlite Industries were the biggest losers in the group. The stocks fell over 3.8 % each. ACC was the biggest gainer in the ...